PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 90957

Title: Treatment-induced neuroendocrine prostate cancer and De Novo neuroendocrine prostate cancer: two variant distinct aggressive tumors, identification, prognosis and survival, genetic and epigenetic factors.

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 07734161

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: China

Author’s Country/Territory: Egypt

Manuscript submission date: 2023-12-18

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2024-01-22 19:26

Reviewer performed review: 2024-01-25 00:12

Review time: 2 Days and 4 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novelty of this manuscript</td>
<td>[ ] Grade A: Excellent</td>
<td>[ ] Grade B: Good</td>
<td>[ ] Grade C: Fair</td>
</tr>
<tr>
<td></td>
<td>[ ] Grade D: No novelty</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
The author systematically elucidates a distinct subtype of prostate cancer, neuroendocrine prostate cancer (NEPC), focusing on its occurrence, characteristics, and prognosis. The author highlights the unfavorable prognosis associated with t-NEPC, emphasizing the need for clinical attention. The article also delves into the relationship between t-NEPC development and genomic, epigenetic, and transcriptional changes, providing a comprehensive understanding of t-NEPC. 1. How is the efficacy of androgen deprivation therapy currently assessed in clinical practice? Are there standardized criteria or indicators to detect t-NEPC at an early stage? 2. The existing diagnostic markers for t-NEPC show no correlation with prognosis or treatment benefits. Are there other relevant indicators that can better assess prognosis and treatment outcomes? 3. Since epigenetic and transcriptional changes are associated with the development of t-NEPC, are there corresponding epigenetic markers or transcriptional sites that can
serve as intervention targets? Can certain gene sequencing techniques be employed for early assessment of disease progression?
Name of journal: World Journal of Clinical Cases

Manuscript NO: 90957

Title: Treatment-induced neuroendocrine prostate cancer and De Novo neuroendocrine prostate cancer: two variant distinct aggressive tumors, identification, prognosis and survival, genetic and epigenetic factors.

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 06269450

Position: Peer Reviewer

Academic degree: MD

Professional title: Chief Physician, Doctor

Reviewer’s Country/Territory: China

Author’s Country/Territory: Egypt

Manuscript submission date: 2023-12-18

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2024-01-22 23:53

Reviewer performed review: 2024-01-28 01:02

Review time: 5 Days and 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[Y] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Novelty of this manuscript</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Good</th>
<th>[ ] Grade C: Fair</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: No novelty</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
The topic of this editorial has a certain novelty. It studies the differences in etiology and
treatment of two types of prostate cancer: NEPC and t-NEPC, as well as related research
progress. But please check the formality of the manuscript carefully, there are some
mistakes. And as an editorial, about half of the references cited are articles from 5 years
ago. Please update the references.